United States

People: MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

12:32pm EDT
Change (% chg)

$1.25 (+2.46%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Gianakakos, Tassos 

Mr. Tassos Anastasios Gianakakos serves as President, Chief Executive Officer, Director of the Company. Prior to joining us, Mr. Gianakakos was senior vice president and chief business officer at MAP Pharmaceuticals, Inc., a biopharmaceutical company, from September 2006 to March 2013 when it was acquired by Allergan PLC. Prior to MAP Pharmaceuticals, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis’ Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, a biocatalyst development company, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co., Inc.’s vaccine division. Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.

Basic Compensation

Total Annual Compensation, USD 459,545
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD 220,600
All Other, USD 424,806
Fiscal Year Total, USD 1,104,950

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Mark Perry


Tassos Gianakakos


June Lee


Jake Bauer


Joseph Lambing


Robert McDowell

As Of  30 Dec 2016